Napsin A Expression in Anaplastic, Poorly Differentiated, and Micropapillary Pattern Thyroid CarcinomasChernock, Rebecca D. MD*,†; El-Mofty, Samir K. DMD, PhD*,†; Becker, Nils MD*; Lewis, James S. Jr MD*,†The American Journal of Surgical Pathology: August 2013 - Volume 37 - Issue 8 - p 1215–1222 doi: 10.1097/PAS.0b013e318283b7b2 Original Articles Abstract Author Information Napsin A is a sensitive and specific marker for pulmonary adenocarcinoma versus squamous cell carcinoma. However, studies have shown that napsin A is also positive in approximately 5% of papillary thyroid carcinomas. The prevalence of napsin A in more aggressive types of thyroid carcinoma is unknown. Napsin A positivity in metastatic thyroid carcinoma, especially in conjunction with thyroid transcription factor-1 (TTF-1), could be misdiagnosed as lung adenocarcinoma. We investigated napsin A, TTF-1, and PAX8 expression in 26 anaplastic, 16 poorly differentiated, and 2 micropapillary pattern thyroid carcinomas. A focal micropapillary component was also present in 3 poorly differentiated and 3 anaplastic thyroid carcinomas. Four of 26 (15%) anaplastic, 2/16 (13%) poorly differentiated, and 2/2 (100%) micropapillary pattern thyroid carcinomas were napsin A positive. Three of the 6 cases (50%) with a focal micropapillary component were napsin A positive (1 of these 3 cases was positive only in the micropapillary component). All napsin A-positive cases were also positive for TTF-1, and all but 1 micropapillary pattern carcinoma were also PAX8 positive. In 1 case, napsin A was positive in the micropapillary component, but PAX8 was only positive in the adjacent poorly differentiated carcinoma. In summary, a minority of anaplastic and poorly differentiated thyroid carcinomas are napsin A positive. More importantly, napsin A expression is more common in carcinomas with a micropapillary component, a pattern shared in common with some lung adenocarcinomas. PAX8 may be diagnostically useful to distinguish these napsin A-positive thyroid carcinomas from lung adenocarcinomas, which are PAX8 negative. Departments of *Pathology and Immunology †Otolaryngology Head and Neck Surgery, Washington University School of Medicine, St Louis, MO Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. Correspondence: Rebecca D. Chernock, MD, Department of Pathology and Immunology, Washington University School of Medicine, 660S Euclid Ave, Campus Box 8118, St Louis, MO (e-mail: firstname.lastname@example.org). © 2013 by Lippincott Williams & Wilkins.